 |
Crescendo Communications is handling IR duties for Silexion Ltd, the Israeli clinical stage oncology-focused biotech that is merging in a SPAC deal with Moringa Acquisition Corp.
The deal, which is expected to close during the third quarter, is valued at $62.5M.
Ilan Levin, CEO of Moringa, said Silexion is on the cutting edge of RNA therapeutics.
Its first-generation Loder product has demonstrated strong results in patients with pancreatic cancer. Loder achieved a median overall survival advantage of 9.3 months over the use of chemotherapy alone.
Levin believes the merger will provide "both our respective shareholders the opportunity to participate in the potential of Silexion’s powerful platform as a public company listed on Nasdaq.”
David Waldman heads New York-based Crescendo, which launched in 2006.
FGS Global represents private equity firm Thoma Bravo as it makes a $4.6B bid for Darktrace, a UK-based cybersecurity artificial intelligence firm.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Have a comment? Send it to 
No comments have been submitted for this story yet.